Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DD-PrEP: Pharmacokinetic Evaluation of Single Dosing With Two F/TAF Tablets
NCT07349758Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Johns Hopkins University. Primary endpoint: Intracellular tenofovir-diphosphate concentrations at 168 hours. Started Jan 2026; status: recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07349758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349758.